Pracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing. Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors.
For the treatment of various forms of cancer.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.